MedTrace Logo

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

NCT05263739 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2025-09-12

No results posted yet for this study

Summary

This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK, and preliminary efficacy and to establish the MTD, if any, and RP2D(s) of ESG206 in adult subjects with B lymphoid malignancies.

Conditions

  • B-cell Lymphoid Malignancies

Interventions

DRUG

ESG206

Administered via intravenous (IV) infusion

Sponsors & Collaborators

  • Escugen (Australia) Biotechnology Pty Ltd

    collaborator UNKNOWN

  • Shanghai Escugen Biotechnology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-08-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05263739 on ClinicalTrials.gov